Posted by Michael Wonder on 12 Jul 2026
Pharvaris announces FDA acceptance of new drug application for deucrictibant IR for on-demand treatment of hereditary angioedema attacks
6 July 2026 - Pharvaris today announced that the US FDA has accepted its new drug application for deucrictibant immediate release 20 mg capsules for the on-demand treatment of hereditary angioedema attacks.
The FDA has set a PDUFA target action date of 23 April 2027.
